loading...| Preferred Name | Pravastatin Sodium | |
| Synonyms |
|
|
| Definitions |
The sodium salt of pravastatin with cholesterol-lowering and potential antineoplastic activities. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. In addition, pravastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cells; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C29375 |
|
| ALT_DEFINITION |
A drug used to lower the amount of cholesterol in the blood and to prevent stroke and heart attack. It is also being studied in the treatment of cancer and other conditions. Pravastatin sodium blocks an enzyme that helps make cholesterol in the body. It may also make tumor cells more sensitive to anticancer drugs. It is a type of HMG-CoA reductase inhibitor, a type of statin, and a type of chemosensitizer. |
|
| CAS_Registry |
81131-70-6 |
|
| CHEBI_ID |
CHEBI:8361 |
|
| Chemical_Formula |
C23H35O7.Na |
|
| code |
C29375 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
The sodium salt of pravastatin with cholesterol-lowering and potential antineoplastic activities. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. In addition, pravastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cells; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades. |
|
| Display_Name |
Pravastatin Sodium |
|
| FDA_UNII_Code |
3M8608UQ61 |
|
| Has_Free_Acid_Or_Base_Form | ||
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Pravastatin Sodium |
|
| Legacy Concept Name |
Pravastatin |
|
| Maps_To |
Pravastatin Sodium |
|
| NCI_Drug_Dictionary_ID |
424450 |
|
| PDQ_Closed_Trial_Search_ID |
424450 |
|
| PDQ_Open_Trial_Search_ID |
424450 |
|
| Preferred_Name |
Pravastatin Sodium |
|
| prefixIRI |
NCIT:C29375 |
|
| prefLabel |
Pravastatin Sodium |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0700474 |
|
| subClassOf |